Literature DB >> 19635892

Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis.

Elizabeth C Barroso1, Valéria G F Pinheiro, Mônica C Façanha, Maria R D Carvalho, Maria E Moura, Creusa L Campelo, Charles A Peloquin, Richard L Guerrant, Aldo A M Lima.   

Abstract

This study evaluates the serum concentrations of rifampin (RMP), isoniazid (INH), and intestinal barrier function in patients with multidrug-resistant tuberculosis (MDR-TB), drug susceptible tuberculosis (DS-TB), and health volunteers (HC; controls). Peak serum concentrations of RMP were significantly lower in MDR-TB and DS-TB as compared with HC (odds ratio [OR] = 3.125, confidence interval [CI] [1.037-9.418] and OR = 4.025, CI [1.207-13.418], respectively). The INH peak serum concentration was not significantly different between MDR-TB versus DS-TB or DS-TB versus HC. The percent of mannitol excretion was significantly lower in the MDR-TB group compared with DS-TB (13.18 versus 16.03, analysis of covariance [ANCOVA], P = 0.0369) and compared with HC (13.18 versus 16.61, ANCOVA, P = 0.0291) the other study groups. These data suggested a lower peak serum concentration of RMP for both MDR-TB and DS-TB as compared with the HC group. The data also showed a lower intestinal area of absorption in patients with tuberculosis and even worse in MDR-TB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19635892

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  14 in total

1.  Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug.

Authors:  Sarah C McLeay; Peter Vis; Rolf P G van Heeswijk; Bruce Green
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

2.  OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.

Authors:  Bani Tamraz; Hisayo Fukushima; Alan R Wolfe; Rüdiger Kaspera; Rheem A Totah; James S Floyd; Benjamin Ma; Catherine Chu; Kristin D Marciante; Susan R Heckbert; Bruce M Psaty; Deanna L Kroetz; Pui-Yan Kwok
Journal:  Pharmacogenet Genomics       Date:  2013-07       Impact factor: 2.089

Review 3.  Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults.

Authors:  Kyle John Wilby; Mary H H Ensom; Fawziah Marra
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

4.  Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB.

Authors:  Christopher Vinnard; Shruthi Ravimohan; Neo Tamuhla; Jotam Pasipanodya; Shashikant Srivastava; Chawangwa Modongo; Nicola M Zetola; Drew Weissman; Tawanda Gumbo; Gregory P Bisson
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

5.  The Influence of Mining and Human Immunodeficiency Virus Infection Among Patients Admitted for Retreatment of Tuberculosis in Northern Tanzania.

Authors:  Stellah G Mpagama; Isaack A Lekule; Alexander W Mbuya; Riziki M Kisonga; Scott K Heysell
Journal:  Am J Trop Med Hyg       Date:  2015-05-26       Impact factor: 2.345

6.  Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.

Authors:  N B Bhatt; C Barau; A Amin; E Baudin; B Meggi; C Silva; V Furlan; B Grinsztejn; A Barrail-Tran; M Bonnet; A M Taburet
Journal:  Antimicrob Agents Chemother       Date:  2014-03-24       Impact factor: 5.191

7.  Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples.

Authors:  Andrew Reckers; Stella Huo; Ali Esmail; Keertan Dheda; Peter Bacchetti; Monica Gandhi; John Metcalfe; Roy Gerona
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2020-12-10       Impact factor: 3.205

8.  Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis.

Authors:  Norah D Ndusilo; Scott K Heysell; Stellah G Mpagama; Jean Gratz; Farida H Segesela; Saumu J Pazia; Xin-Qun Wang; Eric R Houpt; Gibson S Kibiki
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

9.  A Pilot Study of Immune Activation and Rifampin Absorption in HIV-Infected Patients without Tuberculosis Infection: A Short Report.

Authors:  Christopher Vinnard; Isabel Manley; Brittney Scott; Mariana Bernui; Joella Adams; Sheryl Varghese; Isaac Zentner; Michele A Kutzler
Journal:  Tuberc Res Treat       Date:  2017-12-21

10.  Comparative Proteomics of Activated THP-1 Cells Infected with Mycobacterium tuberculosis Identifies Putative Clearance Biomarkers for Tuberculosis Treatment.

Authors:  Benjawan Kaewseekhao; Vivek Naranbhai; Sittiruk Roytrakul; Wises Namwat; Atchara Paemanee; Viraphong Lulitanond; Angkana Chaiprasert; Kiatichai Faksri
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.